Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis

ABSTRACT The rapid emergence of COVID-19 variants of concern (VOCs) has hindered vaccine uptake. To inform policy, we investigated the effectiveness of the BNT162b2 vaccination among adolescents against symptomatic and severe COVID-19 diseases using mostly real-world data (15 studies). We searched international databases until May 2022 and used Cochrane’s risk of bias tools for critical appraisal. Random effects models were used to examine overall vaccine effectiveness (VE) across studies (general inverse-variance) and the effect of circulating VOCs on VE (log relative ratio and VE). Meta-regression assessed the effect of age and time on VE (restricted-maximum likelihood). BNT162b2 VE against PCR-confirmed SARS-CoV-2 was 82.7% (95%CI: 78.37–87.31%). VE was higher for severe (88%) than non-severe (35%) outcomes and declining over time improved following booster dose in omicron era [73%(95%CI:65–81%)]. Fully vaccinated adolescents are protected from COVID-19 circulating VOCs by BNT162b2 especially for the need of critical care or life support.

[1]  C. Wiysonge,et al.  Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis , 2022, Human vaccines & immunotherapeutics.

[2]  S. Ethelberg,et al.  Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study , 2022, PLoS medicine.

[3]  N. Klein,et al.  COVID-19 vaccination protects children and adolescents , 2022, The Lancet Infectious Diseases.

[4]  A. Huppert,et al.  Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study , 2022, The Lancet Infectious Diseases.

[5]  H. D. de Melker,et al.  Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections , 2022, Nature Communications.

[6]  J. McLaughlin,et al.  Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years , 2022, JAMA network open.

[7]  R. Link-Gelles,et al.  Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. , 2022, JAMA.

[8]  A. Pottegård,et al.  Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study , 2022, BMJ.

[9]  S. Sivasampu,et al.  Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia , 2022, International Journal of Infectious Diseases.

[10]  Manish M Patel,et al.  BNT162b2 Protection against the Omicron Variant in Children and Adolescents , 2022, The New England journal of medicine.

[11]  Andrew L. Phillips,et al.  Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[12]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[13]  Reed J. D. Sorensen,et al.  Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 , 2022, The Lancet.

[14]  E. Shapiro,et al.  Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents , 2022, JAMA network open.

[15]  S. Bhatt,et al.  Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study , 2022, The Lancet.

[16]  V. Saliba,et al.  Effectiveness of BNT162b2 against COVID-19 in adolescents , 2022, The Lancet Infectious Diseases.

[17]  B. Senft,et al.  Effects of the COVID-19 Pandemic on Children and Adolescents from the Perspective of Teachers , 2022, Frontiers in Education.

[18]  S. Zeger,et al.  Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.

[19]  N. Sewankambo,et al.  Assessment of Clinical Outcomes Among Children and Adolescents Hospitalized With COVID-19 in 6 Sub-Saharan African Countries , 2022, JAMA pediatrics.

[20]  Manish M Patel,et al.  Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents , 2022, The New England journal of medicine.

[21]  A. Randolph,et al.  Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021 , 2022, MMWR. Morbidity and mortality weekly report.

[22]  Qi Wu,et al.  Safety and efficacy of the COVID-19 vaccine in children and/or adolescents:A meta-analysis , 2022, Journal of Infection.

[23]  L. Bekker,et al.  Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa , 2021, The New England journal of medicine.

[24]  S. Yi,et al.  Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents , 2021, Vaccine.

[25]  Jue Liu,et al.  Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis , 2021, Infectious Diseases of Poverty.

[26]  M. Rämet,et al.  Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age , 2021, The New England journal of medicine.

[27]  M. Hernán,et al.  Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents , 2021, The New England journal of medicine.

[28]  O. A. Ogun,et al.  Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.

[29]  A. Glatman-Freedman,et al.  The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data , 2021, EBioMedicine.

[30]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months , 2021, The New England journal of medicine.

[31]  W. Wang,et al.  Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial , 2021, The Lancet Infectious Diseases.

[32]  R. Pajon,et al.  Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents , 2021, The New England journal of medicine.

[33]  Heshui Shi,et al.  Fibrotic Interstitial Lung Abnormalities at 1-year Follow-up CT after Severe COVID-19 , 2021, Radiology.

[34]  P. Dormitzer,et al.  Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents , 2021, The New England journal of medicine.

[35]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[36]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[37]  C. Knaevelsrud,et al.  Die COVID-19-Pandemie als Herausforderung für die psychische Gesundheit , 2020, Zeitschrift für Klinische Psychologie und Psychotherapie.

[38]  Valentina Telhaj.  Mental Health of Adolescents and Youth , 2019, Journal of Cultural and Religious Studies.

[39]  N. Zdanowicz,et al.  Adolescent health , 2004, The Lancet.

[40]  Wei Chen.  Safety and Immunogenicity of a Recombinant Adenovirus Type-5–Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥ 6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial , 2021 .